{"doi":"10.1111/all.16265","title":"Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population‐based cohort study","abstract":"BACKGROUND: Dupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD. METHODS: In this population-based cohort study, we utilized electronic health records from multiple healthcare organizations across the United States. Pediatric patients (<18 years of age) with a diagnosis of AD initiating dupilumab were propensity-score matched 1:1 to those initiating other systemic agents (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, or systemic corticosteroids). The primary outcomes were new-onset comorbidities emerging during the study period measured by the risk ratio (RR) and its confidence interval (CI). Subgroup analyses were stratified by age (0-5 years, 6-11 years, and 12-17 years), sex, and race. RESULTS: A total of 3575 pediatric patients with AD treated with dupilumab were matched to 3575 patients treated with other systemic agents. The dupilumab cohort was associated with a lowered risk of new-onset atopic comorbidities (including asthma [RR, 0.72; 95% CI, 0.59-0.89] and allergic rhinitis [RR, 0.62; 95% CI, 0.52-0.74]), infections (e.g., skin and soft tissue infection [RR, 0.70; 95% CI, 0.63-0.76] and respiratory tract infection [RR = 0.56; 95% CI, 0.51-0.61]), psychiatric disorders (e.g., mood disorder [RR, 0.52; 95% CI, 0.39-0.70] and anxiety [RR, 0.57; 95% CI, 0.46-0.70], sleep disturbance [RR, 0.60; 95% CI, 0.47-0.77]), neurologic and developmental disorders (e.g., attention deficit hyperactivity disorder [RR, 0.54; 95% CI, 0.38-0.75]). Furthermore, the positive effects are found to be more pronounced in younger children (aged 0-5 years) with AD. CONCLUSIONS: Treatment with dupilumab compared to systemic agents resulted in reductions in AD-related comorbidities in pediatric patients.","journal":"Allergy","year":2024,"id":423070,"datarank":0.7624331472828783,"base_score":3.258096538021482,"endowment":3.258096538021482,"self_citation_contribution":0.4887144807032224,"citation_network_contribution":0.27371866657965593,"self_endowment_contribution":0.4887144807032224,"citer_contribution":0.27371866657965593,"corpus_percentile":73.58242438307418,"corpus_rank":3416,"citation_count":25,"citer_count":19,"citers_with_citation_signal":7,"citers_with_endowment":7,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.5419,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":309177,"name":"Jonathan M. Gaffin","orcid":"0000-0003-2213-4504","position":1,"is_corresponding":false},{"id":1207127,"name":"Elena B. Hawryluk","orcid":"0000-0002-0862-3339","position":2,"is_corresponding":false},{"id":758488,"name":"Hana B. Ruran","orcid":"0009-0007-3964-4961","position":3,"is_corresponding":false},{"id":347995,"name":"Lisa M. Bartnikas","orcid":"0000-0002-5148-3271","position":4,"is_corresponding":false},{"id":469431,"name":"Michiko K. Oyoshi","orcid":"0000-0002-0931-3949","position":5,"is_corresponding":false},{"id":11549,"name":"Lynda C. Schneider","orcid":"0000-0002-5633-0178","position":6,"is_corresponding":false},{"id":317018,"name":"Wanda Phipatanakul","orcid":"0000-0002-0028-8927","position":7,"is_corresponding":false},{"id":859459,"name":"Kevin Sheng‐Kai","orcid":"0000-0002-9394-4144","position":8,"is_corresponding":false},{"id":1207126,"name":"Serena Yun‐Chen Tsai","orcid":"0000-0002-5778-645X","position":0,"is_corresponding":true}],"reference_count":53,"raw_metadata":null,"created_at":"2026-07-19T01:57:56.814994Z","pmid":"39166365","pmcid":"PMC11608558","fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}